| scholarly article | Q13442814 |
| P50 | author | Tanios Bekaii-Saab | Q43376169 |
| Ludmila Katherine Martin | Q43376194 | ||
| Jeffrey M Rose | Q88439111 | ||
| Mark Bloomston | Q114438590 | ||
| P2093 | author name string | Hooman Khabiri | |
| Lai Wei | |||
| Carl Schmidt | |||
| Marlo Blazer | |||
| Anthony Cucci | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? | Q34460461 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study | Q34583973 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| Actual 10-year survival after resection of colorectal liver metastases defines cure. | Q34699863 | ||
| Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis | Q34874473 | ||
| Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma | Q35051942 | ||
| Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group | Q36927159 | ||
| Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. | Q37060054 | ||
| Liver metastases from colorectal cancer: radioembolization with systemic therapy | Q37626421 | ||
| Treatment of colorectal cancer: hepatic metastasis | Q41129817 | ||
| Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection | Q41340184 | ||
| Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases | Q44794355 | ||
| Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study | Q46781981 | ||
| Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. | Q51840650 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | yttrium | Q941 |
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 195-199 | |
| P577 | publication date | 2012-01-24 | |
| P1433 | published in | Clinical Colorectal Cancer | Q332277 |
| P1476 | title | Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases | |
| P478 | volume | 11 |
| Q38169587 | A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. |
| Q99595716 | Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) |
| Q36352452 | Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases |
| Q38398883 | Non-operative therapies for colorectal liver metastases |
| Q47550727 | Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience. |
| Q37525319 | Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres |
| Q87185931 | Recurrence location after resection of colorectal liver metastases influences prognosis |
| Q37525387 | Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response |
Search more.